Xeris Biopharma director granted stock and options
Xeris Biopharma Holdings director Nerissa Kreher received equity-based compensation.
Rhea-AI Filing Summary
Xeris Biopharma Holdings director Nerissa Kreher received equity-based compensation. She was granted 33,582 shares of common stock through restricted stock units under the company’s 2018 Stock Option and Incentive Plan. These RSUs vest in equal annual installments over three years, contingent on continued board service.
She was also granted stock options for 37,910 shares of common stock at an exercise price of $8.00 per share, expiring on July 1, 2036. These options vest in equal annual installments over three years, also subject to continued service on the board. The filing shows no open-market buying or selling, only compensation-related awards.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 71,492 shares
Grant/Award
2 txns
Insider
KREHER NERISSA
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 37,910 | $8.00 | $303K |
| Grant/Award | Common Stock | 33,582 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 37,910 contracts (Direct);
Common Stock — 33,582 shares (Direct)
Footnotes (2)
- F1. These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued service on the Company's Board of Directors through such vesting date.
- F2. These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in equal annual installments over three years, subject to continued service on the Company's Board of Directors through such vesting date.
Key Figures
RSU grant: 33,582 shares
Option grant size: 37,910 options
Option exercise price: $8.00 per share
+3 more
6 metrics
RSU grant
33,582 shares
Restricted stock units granted to director as of July 1, 2026
Option grant size
37,910 options
Stock options granted on common stock as of July 1, 2026
Option exercise price
$8.00 per share
Strike price for stock options granted to director
Option expiration
July 1, 2036
Expiration date of granted stock options
Common shares after RSU grant
33,582 shares
Total common stock holdings following RSU transaction
Options after grant
37,910 options
Total derivative holdings following option grant
Key Terms
restricted stock unit, 2018 Stock Option and Incentive Plan, vest in equal annual installments, Stock Option (Right to Buy), +1 more
5 terms
restricted stock unit financial
"These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
2018 Stock Option and Incentive Plan financial
"These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan"
vest in equal annual installments financial
"These shares shall vest in equal annual installments over three years, subject to continued service"
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) transaction reported as a derivative security grant"
exercise price financial
"These stock options were acquired pursuant to a grant under the Plan with an $8.00 exercise price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
What did Xeris Biopharma (XERS) director Nerissa Kreher report in this Form 4?
Director Nerissa Kreher reported equity compensation awards, not open-market trades. She received 33,582 restricted stock units and stock options for 37,910 shares, all granted under Xeris Biopharma’s 2018 Stock Option and Incentive Plan as part of her board compensation.
What stock options were granted to Nerissa Kreher by Xeris Biopharma (XERS)?
She received stock options covering 37,910 shares of Xeris Biopharma common stock at an exercise price of $8.00 per share. The options were granted as compensation and give her the right, but not obligation, to buy shares before the July 1, 2036 expiration date.
How do the vesting terms work for Nerissa Kreher’s Xeris Biopharma equity awards?
Both the 33,582 restricted stock units and the 37,910 stock options vest in equal annual installments over three years. Vesting is contingent on Nerissa Kreher’s continued service on Xeris Biopharma’s board, meaning she earns portions of the awards each year she remains a director.
When do Nerissa Kreher’s Xeris Biopharma stock options expire and at what price?
Her stock options expire on July 1, 2036 and have an exercise price of $8.00 per share. She can choose to exercise them before that date, subject to vesting, to purchase Xeris Biopharma common shares at that fixed price regardless of future market prices.
AI-generated analysis. How Rhea-AI works. Not financial advice.
